Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.
The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.
The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.
Publications found:
193
Sort by:
Insulin biosimilars Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars), By Disease Indication Type (Type I Diabetes, Type II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End user (Hospitals, Ambulatory Surgical Centers, Others), By Region and Competition, 2020-2030F
US$ 4,500.00
The Global Insulin biosimilars Market, valued at USD 1.55 Billion in 2024, is projected to experience a CAGR of 7.30% to reach USD 2.37 Billion by 2030. Insulin biosimilars are biological medicines hi...
November 2025
187 pages
Oncology Biosimilars Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F
US$ 4,500.00
The Global Oncology Biosimilars Market, valued at USD 4.54 Billion in 2024, is projected to experience a CAGR of 6.94% to reach USD 6.79 Billion by 2030. Oncology biosimilars are biological products d...
November 2025
185 pages
Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Application (Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications), By Distribution Channel
US$ 3,950.00
The Adalimumab, Infliximab And Etanercept Biosimilars Market is valued at USD 6.4 billion in 2025 and is projected to grow at a CAGR of 16.7% to reach USD 25.6 billion by 2034.The adalimumab, inflixim...
October 2025
160 pages
Biologic & Biosimilar Ra Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis By Source (Microbial, Mammalian, Other Sources), By Disease (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases), By Manufacturing, By Mode Of Purchase, By Distribution Channel
US$ 3,950.00
The Biologic & Biosimilar Ra Drugs Market is valued at USD 12.1 billion in 2025 and is projected to grow at a CAGR of 5.5% to reach USD 19.5 billion by 2034.The market for biologic and biosimilar rheu...
October 2025
160 pages
Biosimilar Growth Hormones Market Outlook 2025-2034: Market Share, and Growth Analysis By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications), By Distribution Channel
US$ 3,950.00
The Biosimilar Growth Hormones Market is valued at USD 1010.4 million in 2025 and is projected to grow at a CAGR of 8.7% to reach USD 2131.9 million by 2034.The Biosimilar Growth Hormones Market is ex...
October 2025
160 pages
Biosimilar Hormones Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications), By Distribution Channel
US$ 3,950.00
The Biosimilar Hormones Market is valued at USD 7.9 billion in 2025 and is projected to grow at a CAGR of 22.8% to reach USD 50.3 billion by 2034.The Biosimilar Hormones Market is experiencing robust...
October 2025
160 pages
Biosimilar Interleukins Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications), By Distribution Channel
US$ 3,950.00
The Biosimilar Interleukins Market is valued at USD 9.3 billion in 2025 and is projected to grow at a CAGR of 34.7% to reach USD 135.9 billion by 2034.The Biosimilar Interleukins Market is emerging as...
October 2025
160 pages
Biosimilar Monoclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (Synthetic Chemicals, Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Application
US$ 3,950.00
The Biosimilar Monoclonal Antibodies Market is valued at USD 9.3 billion in 2025 and is projected to grow at a CAGR of 14% to reach USD 30.3 billion by 2034.The Biosimilar Monoclonal Antibodies Market...
October 2025
160 pages
Oral Biologics & Biosimilar Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type, By Distribution Channel
US$ 3,950.00
The Oral Biologics & Biosimilar Drugs Market is valued at USD 10.5 billion in 2025 and is projected to grow at a CAGR of 18.7% to reach USD 49.1 billion by 2034.The oral biologics and biosimilar drugs...
October 2025
160 pages
Oral Biologics & Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Therapies), By Disease (Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases), By Molecule Type, By Distribution Channel
US$ 3,950.00
The Oral Biologics & Biosimilars Market is valued at USD 7.7 trillion in 2025 and is projected to grow at a CAGR of 16.2% to reach USD 29.8 trillion by 2034.The oral biologics and biosimilars market h...
October 2025
160 pages
Remicade Biosimilar Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (100mg/10ml, 500mg/50ml), By Disease Indication (Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis), By Application
US$ 3,950.00
The Remicade Biosimilar Market is valued at USD 5.8 billion in 2025 and is projected to grow at a CAGR of 21.7% to reach USD 34 billion by 2034.The Remicade Biosimilar Market has gained substantial mo...
October 2025
160 pages
Trastuzumab Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Products), By Indication (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications), By Distribution Channel
US$ 3,950.00
The Trastuzumab Biosimilars Market is valued at USD 8.1 billion in 2025 and is projected to grow at a CAGR of 24.1% to reach USD 56.6 billion by 2034.The Trastuzumab Biosimilars Market has emerged as...
October 2025
160 pages
Global Biosimilars Market Growth 2025-2031
US$ 3,660.00
The global Biosimilars market size is predicted to grow from US$ 9192 million in 2025 to US$ 25670 million in 2031; it is expected to grow at a CAGR of 18.7% from 2025 to 2031. The impact of the lates...
October 2025
155 pages
Global Oncology Biosimilars-Pipeline Insights - 2025 -2033
US$ 4,350.00
Oncology BiosimilarsIn recent years, cancer cases are increasing at a very rapid phase globally. The high cost of treatment of existing cancer therapeutics raises the interest in biosimilars.Nearly ev...
October 2025
180 pages
Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Therapeutic Area (Oncology, Blood Disorders), By Service, By Region, And Segment Forecasts, 2025 - 2033
US$ 5,950.00
Biosimilar Contract Manufacturing Market The global biosimilar contract manufacturing market size was estimated at USD 7.84 billion in 2024 and is projected to reach USD 25.19 billion by 2033, growing...
September 2025
180 pages
Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), By Region and Competition, 2020-2030F
US$ 4,500.00
Market Overview Global Biosimilar Contract Manufacturing Market was valued at USD 9.37 billion in 2024 and is expected to reach USD 23.54 billion by 2030 with a CAGR of 16.59% during the forecast per...
August 2025
185 pages
Oncology Biosimilars Market Report by Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others), and Region 2025-2033
US$ 2,999.00
The global oncology biosimilars market size reached USD 5.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.2 Billion by 2033, exhibiting a growth rate (CAGR) of 21.15...
August 2025
140 pages
Biosimilar Testing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service Type (Analytical Testing, Clinical Testing), By Molecule Type (Monoclonal Antibodies, Recombinant Hormones, Insulin, Interferons, Enzymes, Others), By Therapeutic Area (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Neurology, Others), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Others), By Region and Competition, 2020-2030F
US$ 4,500.00
Market Overview The Global Biosimilar Testing Services Market was valued at USD 1.53 Billion in 2024 and is projected to reach USD 3.03 Billion by 2030, growing at a CAGR of 12.04%. This growth is dri...
July 2025
181 pages
Europe Biosimilars Market - 2025-2033
US$ 2,499.00
Europe Biosimilars Market reached US$ 5.96 billion in 2024 and is expected to reach US$ 52.98 billion by 2033, growing with a CAGR of 27.70% during the forecast period 2026-2033. The Europe Biosimilar...
July 2025
44 pages
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
US$ 2,970.00
... the forecast period.” The biosimilars market by product, is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected ...
June 2025
392 pages
Global Biosimilars and Biologics Market - 2025-2033
US$ 4,350.00
Biosimilars and Biologics Market Size The global biosimilars and biologics market size reached US$ 531.45 Billion in 2024 and is expected to reach US$ 1,773.77 Billion by 2033, growing at a CAGR of 14...
May 2025
159 pages
Biosimilars: Global Markets
US$ 4,650.00
... emerging framework in regulated markets, as well as comparisons of biosimilar guidelines in Europe, the U.S., Japan, Canada, as well the guidelines developed by the - World Health Organization Technology trends and ...
March 2025
219 pages
Pegfilgrastim Biosimilars Market - 2024-2031
US$ 3,400.00
The Pegfilgrastim Biosimilars Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to delive...
October 2023
51 pages
Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity
US$ 2,295.00
Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of $140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incide...
November 2021
116 pages
Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity
US$ 2,295.00
Europe biosimilars market was valued at $5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic di...
November 2021
121 pages
Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity
US$ 2,720.00
Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases d...
November 2021
180 pages
North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity
US$ 2,295.00
North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising inciden...
November 2021
116 pages
Asia Pacific BOPP and BOPET films Market Analysis: Plant Capacity, Production, Operating Efficiency, Process, Demand & Supply, Application, Sales Channel, Region, Competition, Trade, Customer & Price Intelligence Market Analysis, 2015-2030
US$ 4,000.00
Asia Pacific BOPP and BOPET films demand stood at 2.09 Million Tonnes in 2020 and is forecast to reach 3.476 Million Tonnes by 2030, growing at a healthy CAGR of 5.04% until 2030. The rise in e-commer...
June 2021
-
Global Glycobiology Market, By Product (Enzymes, Instruments, Reagents and Kits), By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others), By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Region, Competition, Forecast & Opportunities, 2025
US$ 4,500.00
Global glycobiology market was valued at USD 938.76 Million in 2019 and is expected to grow at a double digit CAGR of 13.83% during the forecast period. The global glycobiology market is driven by the...
January 2021
224 pages
Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), By Manufacturing (In-house, Contract) & Indication (Offsite Treatment, Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, and Other Diseases), By Geography (North America, Europe, APAC, and RoW) Global Opportunity Analysis and Industry Forecast up to 2026
US$ 3,250.00
Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and...
July 2020
85 pages
Global Biosimilars - Market and Technology Forecast to 2028
US$ 3,995.00
Biosimilars have a very complex molecular structure and they have similar characteristics as compared to their reference medicine. Biosimilars are mainly used to derive known effective medicinal produ...
June 2020
256 pages
Japan Biosimilars- Landscape Today Outlook Tomorrow
US$ 4,500.00
“Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinctAfter a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Ch...
January 2020
156 pages
Europe Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition, Forecast & Opportunities, 2024
US$ 4,000.00
Europe biosimilar insulin glargine and lispro market is projected to reach $ 1.9 billion by 2024 owing to rising levels of obesity, growing expenditure on healthcare and increasing adoption of sedenta...
January 2020
86 pages
US Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025
US$ 2,400.00
... Phase: 28 Biosimilars Marketed Biosimilars Clinical Insight by Company & Indication: 9 Biosimilars Biosimilars Market Opportunity: US$ 5 Billion FDA Rules & Regulations For Biosimilars Development & Market Approved & Marketed Biosimilars: Clinical Insight, Price & Dosage 'US Biosimilars Market, Dosage, Price ...
April 2019
300 pages
Global G-CSF Biosimilars Market Size study, by Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies) and Regional Forecasts 2018-2025
US$ 3,750.00
... – 2018 to 2025 Target Audience of the Global G-CSF Biosimilars Market in Market Study: Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value ...
February 2019
200 pages
Biosimilars: Market Research Report
US$ 5,450.00
This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, ... forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary ...
January 2019
243 pages
ASEAN and China Biosimilars Market by Molecule Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibody, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, and Peptide), and Application (Blood Disorder, Oncology Disease, Chronic & Autoimmune Disease, Growth Hormone Deficiency, and Others): Opportunity Analysis and Industry Forecast, 2017 - 2025
US$ 3,200.00
... the expansion of the biosimilars market across ASEAN and China. The ASEAN and China biosimilars market is segmented into molecule ... market is analyzed across China and ASEAN region. Key Benefits ASEAN and China Biosimilars Market: The study provides an in-depth analysis of the ASEAN and China biosimilars market ...
November 2018
130 pages
